(Q28084585)

language of work or name

1 reference

October 2015

1 reference

Journal of the National Cancer Institute

published in

1 reference

volume

107

1 reference

issue

10

1 reference

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV212

Mechanisms of tamoxifen resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV212

Endocrine-responsive breast cancer and strategies for combating resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV212

Estrogen-receptor biology: continuing progress and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV212

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV212

Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV212

Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, mult

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV212

Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV212

Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV212

Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV212

Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV212

Combination anastrozole and fulvestrant in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV212

Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV212

Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV212

Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV212

Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV212

Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV212

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV212

Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV212

Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal a

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV212

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV212

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV212

mTOR and cancer: insights into a complex relationship

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV212

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV212

Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV212

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV212

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV212

Emerging targeted agents in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV212

Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV212

Insulin-like growth factor receptor levels are regulated by cell density and by long term estrogen deprivation in MCF7 human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV212

Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV212

Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV212

Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV212

Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV212

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV212

Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV212

Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV212

FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV212

AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV212

Functional activation of the estrogen receptor-α and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV212

Significance of ER-Src axis in hormonal therapy resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV212

Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV212

CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV212